All In Biotech

Drug Trial Radar · NCT04307381

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

An Open-Label Extension Study of ISIS 721744 in Patients With Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Mar 31, 2020

Primary completion

Jan 24, 2025

Study completion Jan 24, 2025

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Mar 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).

Conditions

  • Hereditary Angioedema

Interventions

  • DonidalorsenDrug

    Donidalorsen administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to Week 221
  2. Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory AssessmentsTime frame: Up to Week 221
  3. Percentage of Participants With Clinically Meaningful Changes in Vital SignsTime frame: Up to Week 221
  4. Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) ParametersTime frame: Up to Week 221
  5. Percentage of Participants Who Received At Least One Concomitant MedicationTime frame: Up to Week 221

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Ionis Investigative Site

    Scottsdale, Arizona

  • Ionis Investigative Site

    Santa Monica, California

  • Ionis Investigative Site

    Plymouth, Minnesota

  • Ionis Investigative Site

    Cincinnati, Ohio

  • Ionis Investigative Site

    Hershey, Pennsylvania

  • Ionis Investigative Site

    Dallas, Texas

  • Ionis Investigative Site

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.